Stonebridge Capital Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.1M Sell
150,773
-3,981
-3% -$460K 1.27% 22
2025
Q4
$16.3M Buy
154,754
+1,807
+1% +$170K 1.13% 29
2025
Q3
$12.8M Sell
152,947
-130
-0.1% -$10.7K 0.92% 37
2025
Q2
$12.1M Sell
153,077
-1,637
-1% -$130K 0.92% 38
2025
Q1
$13.9M Buy
154,714
+7,570
+5% +$707K 1.13% 31
2024
Q4
$14.6M Buy
147,144
+2,777
+2% +$286K 1.18% 28
2024
Q3
$16.4M Buy
144,367
+7,612
+6% +$904K 1.34% 24
2024
Q2
$16.9M Buy
136,755
+3,234
+2% +$417K 1.49% 20
2024
Q1
$17.6M Buy
133,521
+5,212
+4% +$642K 1.58% 17
2023
Q4
$14M Buy
128,309
+4,464
+4% +$463K 1.4% 18
2023
Q3
$12.7M Buy
123,845
+1,901
+2% +$205K 1.4% 21
2023
Q2
$14.1M Sell
121,944
-3,949
-3% -$448K 1.49% 17
2023
Q1
$13.4M Sell
125,893
-792
-0.6% -$85.5K 1.53% 15
2022
Q4
$14.1M Sell
126,685
-1,102
-0.9% -$113K 1.67% 13
2022
Q3
$11M Buy
127,787
+525
+0.4% +$46.9K 1.42% 20
2022
Q2
$11.6M Sell
127,262
-611
-0.5% -$54.2K 1.41% 18
2022
Q1
$10.5M Buy
127,873
+5,565
+5% +$439K 1.13% 33
2021
Q4
$9.37M Buy
122,308
+1,519
+1% +$121K 1.04% 38
2021
Q3
$9.07M Sell
120,789
-99,100
-45% -$7.54M 1.1% 35
2021
Q2
$17M Buy
219,889
+109,145
+99% +$8.12M 1.08% 36
2021
Q1
$8.15M Buy
110,744
+11,063
+11% +$816K 1.08% 36
2020
Q4
$7.78M Buy
99,681
+4,551
+5% +$348K 1.18% 31
2020
Q3
$7.53M Buy
95,130
+2,322
+3% +$182K 1.35% 27
2020
Q2
$6.85M Buy
92,808
+1,301
+1% +$97.9K 1.27% 27
2020
Q1
$6.72M Buy
91,507
+8,134
+10% +$639K 1.42% 19
2019
Q4
$7.24M Sell
83,373
-1,948
-2% -$160K 1.18% 30
2019
Q3
$6.85M Sell
85,321
-1,664
-2% -$133K 1.18% 29
2019
Q2
$6.96M Sell
86,985
-4,334
-5% -$332K 1.24% 27
2019
Q1
$7.25M Buy
91,319
+410
+0.5% +$30.7K 1.35% 24
2018
Q4
$6.63M Sell
90,909
-1,425
-2% -$101K 1.55% 20
2018
Q3
$6.25M Buy
92,334
+534
+0.6% +$34K 1.26% 29
2018
Q2
$5.32M Buy
91,800
+2,705
+3% +$153K 1.16% 34
2018
Q1
$4.63M Buy
89,095
+4,661
+6% +$252K 1.07% 35
2017
Q4
$4.53M Buy
84,434
+5,147
+6% +$285K 1.04% 37
2017
Q3
$4.84M Buy
79,287
+4,526
+6% +$274K 1.19% 27
2017
Q2
$4.57M Buy
74,761
+2,000
+3% +$122K 1.2% 25
2017
Q1
$4.41M Buy
72,761
+2,058
+3% +$125K 1.2% 24
2016
Q4
$3.97M Buy
70,703
+3,396
+5% +$199K 1.18% 28
2016
Q3
$4.01M Buy
67,307
+2,803
+4% +$164K 1.25% 20
2016
Q2
$3.55M Buy
64,504
+5,166
+9% +$275K 1.2% 25
2016
Q1
$3M Buy
59,338
+2,438
+4% +$119K 1.06% 32
2015
Q4
$2.87M Buy
56,900
+5,451
+11% +$275K 1.05% 33
2015
Q3
$2.42M Buy
51,449
+2,955
+6% +$157K 0.98% 35
2015
Q2
$2.63M Buy
48,494
+3,176
+7% +$178K 1.01% 38
2015
Q1
$2.49M Buy
45,318
+6,365
+16% +$360K 0.96% 41
2014
Q4
$2.11M Buy
38,953
+367
+1% +$20.4K 0.87% 43
2014
Q3
$2.18M Buy
38,586
+999
+3% +$56.1K 0.96% 39
2014
Q2
$2.08M Buy
37,587
+1,734
+5% +$94.6K 0.94% 40
2014
Q1
$1.94M Buy
35,853
+1,948
+6% +$101K 0.95% 41
2013
Q4
$1.62M Buy
+33,905
New +$1.55M 0.83% 46

Other funds holding MRK

Stonebridge Capital Advisors's MRK Position: Q1 2026 in Review

Stonebridge Capital Advisors reduced its Merck (MRK) stake by 2.6% in Q1 2026, selling an estimated $460K and leaving 150,773 shares worth $18.1M. The position accounts for 1.27% of the portfolio, ranked #22.

Stonebridge Capital Advisors first reported a position in MRK in Q4 2013 and has held it in 50 quarters since. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Stonebridge Capital Advisors held 150,773 shares of Merck worth $18.1M as of Q1 2026.
  • Stonebridge Capital Advisors sold 3,981 Merck shares in Q1 2026, an estimated $460K.
  • Merck made up 1.27% of Stonebridge Capital Advisors's portfolio in Q1 2026, its #22 holding.
  • Stonebridge Capital Advisors first reported a position in Merck in Q4 2013 and has held it in 50 quarters since.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Stonebridge Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.